Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer

Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas
Clinical and Translational Medicine · Wiley · 2026-11-02 · DOI: 10.1002/ctm2.70890

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles